GT20029- koniec II fazy badań.

[dhttrash 3]

Kintor zakończył II fazę badań nad GT20029. Badanie prowadzono na 180 mężczyznach z AGA na terenie USA i Chin. Wyniki są zaskakująco... pozytywne. Jedna grupa przyjmowała lek dwa razy  w tygodniu, druga codziennie.

Cytat: ,,In terms of efficacy, GT20029 tincture demonstrated statistically significant therapeutic efficacy and clinical significance compared to placebo in both the QD and BIW dosing cohorts. After 12 weeks of treatment, the 0.5% QD GT20029 group showed an increase of 16.80 hairs/cm² from baseline, which was 6.69 hairs/cm² more than the placebo group, with statistically significant results (P<0.05). The TAHC of GT20029 1.0% BIW group showed an increase of 11.94 hairs/cm² from baseline, which was 7.36 hairs/cm² more than the placebo, also yielding statistically significant results (P<0.05). For the BIW cohort, the study indicated a dose-response relationship among different doses of GT20029.''

https://en.kintor.com.cn/news/253.html